TaiRx

TaiRx EBITDA per Share

The EBITDA per Share of TaiRx (6580.TWO) as of Oct 16, 2026 is -2.14 TWD. In the previous year, EBITDA per Share was -1.32 TWD — a change of 62.50% (lower).

EBITDA per Share

-2.14TWD

YoY

62.50%

Last updated:

EBITDA per Share of TaiRx is 2025 -2.14 TWD. EBITDA per Share of TaiRx was 2024 -1.32 TWD. It decreases by 62.50% lower compared to the previous year.

The TaiRx EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-3.46 TWD
Jan 1, 2019
-2.70 TWD
Jan 1, 2020
-2.42 TWD
Jan 1, 2021
-1.43 TWD
Jan 1, 2022
-2.38 TWD
Jan 1, 2023
-2.28 TWD
Jan 1, 2024
-1.32 TWD
Jan 1, 2025
-2.14 TWD
The TaiRx EBITDA per Share history
YEAREBITDA per ShareYoY
-2.14TWD+62.50%
-1.32TWD-42.20%
-2.28TWD-4.19%
-2.38TWD+66.41%
-1.43TWD-40.86%
-2.42TWD-10.24%
-2.70TWD-21.94%
-3.46TWD+63.69%
-2.11TWD+4.55%
-2.02TWD+15.24%
-1.75TWD-32.93%
-2.61TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TaiRx Stock analysis

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

EBITDA per Share of TaiRx is -2.14 TWD in 2025.

EBITDA per Share of TaiRx changed from -1.32 TWD to -2.14 TWD, representing a 62.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share TaiRx since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — TaiRx

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — TaiRx